Clinical Efficacy and Cholesterol-Lowering Effects of Inclisiran
Bibliographic record
Abstract
Inclisiran, a drug developed by Novartis, is a recent medication designed to alleviate cardiovascular disease symptoms through improving low-density lipoprotein cholesterol levels. Mechanistically, inclisiran is a chemically synthesized small interfering RNA (siRNA) molecule targeting serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9), resulting in degradation of the LDL receptor. Positive, large-scale clinical trials on the use of inclisiran demonstrate the drug’s efficacy in reducing LDL cholesterol levels in patients afflicted with cardiovascular disease. Moreover, Novartis and the National Health Services (NHS) of the UK have very recently come to an agreement (September 1st, 2021) on the drug’s utility, as the NHS has enabled inclisiran’s use in more than 300,000 patients with a history of cardiovascular disease. However, despite the promising clinical trials on inclisiran as well as its use in the UK, the U.S. Food and Drug Administration (FDA) has yet to approve the drug as a treatment strategy for cardiovascular disease. This review will analyze and discuss the clinical efficacy of inclisiran based on the recent clinical evidence for its pharmacological use in the treatment of cardiovascular diseases. Key words: Inclisiran, efficacy, cholesterol-lowering
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".